<DOC>
	<DOCNO>NCT01459315</DOCNO>
	<brief_summary>The purpose study describe drug concentration blood plasma , rectal fluid , rectal tissue , seminal fluid HIV negative men follow single multiple dos investigational HIV medication know GSK1349572 ( dolutegravir ) .</brief_summary>
	<brief_title>GSK1349572 Exposure Blood , Seminal Fluid , Rectal Fluid Tissue Healthy Male Subjects</brief_title>
	<detailed_description>The purpose study determine first dose steady-state concentration GSK1349572 seminal fluid , rectal mucosal fluid , rectal tissue compare blood plasma ( BP ) HIV-1 negative male . GSK1349572 investigational next generation integrase inhibitor currently Phase III trial . Understanding concentration GSK1349572 multiple male biological compartment inform role prevent HIV infection make HIV-infected person less likely transmit virus , protect uninfected person acquire virus .</detailed_description>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Healthy male subject age 18 49 year , inclusive , intact genital tract gastrointestinal tract . Body Mass Index ( BMI ) 18 30 kg/m2 ; total body weight great 50 kg ( 110 lb ) . Evidence personally sign date informed consent document Willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Subjects history gastrectomy , colostomy , ileostomy , procedure alter gastrointestinal tract . Subjects history vasectomy , prostatectomy , procedure alter male reproductive tract . Subjects inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) , irritable bowel syndrome , abnormality colorectal mucosa , significant colorectal symptom ( ) Subject unwilling refrain sexual activity 72 hour study visit Day 0 discharge study . Subject unwilling refrain rectal insertion medical/recreation device product receptive anal intercourse , 72 hour study visit Day 0 7 day last biopsy . History febrile illness within 14 day prior first dose . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . A positive result HIV , Hepatitis B surface antigen Hepatitis B core antibody screen test antihepatitis C virus serology A positive test syphilis , rectal gonorrhea , chlamydia , HSV2 ( active lesion ) screen . Current alcohol consumption exceed 14 drink [ 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) spirit ] per week unwilling abstain alcohol use 48 hour prior first dose study medication followup visit . History regular use tobacco nicotinecontaining product exceed equivalent 5 cigarette per day within three month prior screen unwilling abstain cigarette smoke completely visit . Treatment investigational drug within 4 month precede first dose trial medication . Participated rectal biopsy study 12 month precede first dose trial medication . Use clinically significant prescription nonprescription drug within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication Blood donation approximately 1 pint ( ≥473 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . History confirm allergy prescription nonprescription product . Unable unwilling swallow oral medication . History bleed clot disorder include disseminate intravascular coagulation , hemophilia HenochSchönlein purpura ( allergic purpura ) , hereditary hemorrhagic telangiectasia , thrombocytopenia , thrombophilia Von Willebrand 's disease . The subject 's blood pressure outside range 90140/4590 mmHg , heart rate outside range 45100 bpm . Clinically significant abnormality pulse conduction observe ECG Unwilling unable comply dietary restriction Any reason condition would make participation study unsafe , complicate interpretation study outcome data , interfere achieve study objective .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Male</keyword>
	<keyword>GSK1349572</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>DTG</keyword>
	<keyword>Integrase</keyword>
	<keyword>HIV</keyword>
</DOC>